Cambridge Investment Research Advisors
HUMA icon

Cambridge Investment Research Advisors’s Humacyte HUMA Stock Holding History

Cambridge Investment Research Advisors’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-23,729
Closed -$41K – 3883
2025
Q3 		$41K Sell
23,729
-5,067
-18% -$9.93K ﹤0.01% 3666
2025
Q2 		$60K Buy
28,796
+14,806
+106% +$28.4K ﹤0.01% 3521
2025
Q1 		$24K Sell
13,990
-1,698
-11% -$6.38K ﹤0.01% 3442
2024
Q4 		$79K Buy
15,688
+2,388
+18% +$11.8K ﹤0.01% 3345
2024
Q3 		$72K Buy
13,300
+2,273
+21% +$15K ﹤0.01% 3302
2024
Q2 		$53K Buy
+11,027
New +$57.4K ﹤0.01% 3214

Other funds holding HUMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Cambridge Investment Research Advisors's HUMA Position: Q4 2025 in Review

Cambridge Investment Research Advisors sold out of Humacyte (HUMA) in Q4 2025, closing a stake of 23,729 shares — an estimated $41K sold.

Cambridge Investment Research Advisors first reported a position in HUMA in Q2 2024 and held it in 6 quarters. The position peaked at $79K in Q4 2024. 147 funds tracked by Wall St. Rank hold HUMA as of Q4 2025.

  • Cambridge Investment Research Advisors reported no remaining Humacyte position as of Q4 2025 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 23,729 Humacyte shares in Q4 2025, an estimated $41K.
  • Cambridge Investment Research Advisors first reported a position in Humacyte in Q2 2024 and held it in 6 quarters.
  • Cambridge Investment Research Advisors's Humacyte position peaked at $79K in Q4 2024.
  • 147 funds tracked by Wall St. Rank held Humacyte as of Q4 2025.

Based on Cambridge Investment Research Advisors's 13F filing for Q4 2025, filed 5 Feb 2026.